



(12) Translation of  
European patent specification

(11) NO/EP 3388111 B1

NORWAY

(19) NO  
(51) Int Cl.  
*A61P 35/00 (2006.01)*  
*A61K 31/285 (2006.01)*  
*A61K 31/455 (2006.01)*  
*A61K 31/60 (2006.01)*  
*A61K 38/06 (2006.01)*

**Norwegian Industrial Property Office**

---

(45) Translation Published 2022.01.31

(80) Date of The European Patent Office Publication of the Granted Patent 2021.09.29

(86) European Application Nr. 18174817.9

(86) European Filing Date 2009.08.14

(87) The European Application's Publication Date 2018.10.17

(30) Priority 2008.08.20, US, 189511 P

(84) Designated Contracting States: AT ; BE ; BG ; CH ; CY ; CZ ; DE ; DK ; EE ; ES ; FI ; FR ; GB ; GR ; HR ; HU ; IE ; IS ; IT ; LI ; LT ; LU ; LV ; MC ; MK ; MT ; NL ; NO ; PL ; PT ; RO ; SE ; SI ; SK ; SM ; TR

(62) Divided application EP2321012, 2009.08.14

(73) Proprietor Solasia Pharma K.K., 4F, Sumitomo Fudosan Shiba-koen Tower 2-11-1 Shiba-koen Minato-ku, Tokyo 105-0011, Japan

(72) Inventor SCHWARTZ, Brian, Eric, 18 October Hill Road, Woodbridge, CT Connecticut 06525, USA  
LEWIS, Jonathan, 1522 Fairfield Beach Road, Fairfield, CT Connecticut 06824, USA  
KOMARNITSKY, Philip, B., 175 Eliot Street, Chestnut Hill, MA Massachusetts 02467, USA

(74) Agent or Attorney BRYN AARFLOT AS, Stortingsgata 8, 0161 OSLO, Norge

---


(54) Title **ORGANOARSENIC COMPOUND FOR THE TREATMENT OF CANCER**

(56) References  
Cited: US-A1- 2006 128 682  
WO-A2-2007/082104  
Craig et al.: "Phase II trial of darinaparsin in leukemias and lymphomas", AACR Meeting Abstracts Online , April 2008 (2008-04), XP002657429, Retrieved from the Internet: URL:[http://www.aacrmeetingabstracts.org/cgi/content/meeting\\_abstract/2008/1\\_Annual\\_Meeting/5527?maxtoshow=&hits=10&RESULTFORMA T=&author1=craig&andorexactfulltext=and&searchid=1&FIRSTINDEX=0&sortspec=relevance&resource type=HWCIT](http://www.aacrmeetingabstracts.org/cgi/content/meeting_abstract/2008/1_Annual_Meeting/5527?maxtoshow=&hits=10&RESULTFORMA T=&author1=craig&andorexactfulltext=and&searchid=1&FIRSTINDEX=0&sortspec=relevance&resource type=HWCIT) [retrieved on 2011-08-22]

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (<http://worldwide.espacenet.com>) or via the search engine on our website here: <https://search.patentstyret.no/>

**PATENTKRAV**

## 1. Forbindelse med struktur



5

eller et farmasøytisk akseptabelt salt derav,  
for anvendelse i behandlingen av et lymfom valgt fra perifert T-celle  
lymfom (PTCL) hos et individ som tidligere er behandlet for lymfom,  
hvor en dose av forbindelsen er 300 mg/m<sup>2</sup>,  
10 hvor forbindelsen er for intravenøs administrering.

2. Forbindelse for anvendelse ifølge krav 1, hvor forbindelsen er for  
administrering daglig i fem dager hver fjerde uke.

15

3. Forbindelse for anvendelse ifølge krav 2, hvor forbindelsen er for  
administrering daglig i fem påfølgende dager hver fjerde uke.

4. Anvendelse av en forbindelse som definert i krav 1 i fremstillingen av  
et medikament for behandling av et lymfom valgt fra perifert T-celle  
20 lymfom (PTCL) hos et individ tidligere behandlet for lymfom,  
hvor en dose av forbindelsen er 300 mg/m<sup>2</sup>,  
hvor medikamentet er for intravenøs administrering.

5. Anvendelse ifølge krav 4, hvor medikamentet er for administrering  
25 daglig i fem dager, og spesielt i fem påfølgende dager, hver fjerde uke.